Indicators

Category

HR (95% CI)

p-value

Overall Survival

Months

%

Age, years

30-39

1

0.33350

17.5

30.0

40-49

0.81 (0.17-3.82)

16.5

30.7

50-59

0.96 (0.24-3.83)

21.7

9.4

60-69

0.99 (0.25-3.93)

18.0

21.9

70+

1.77 (0.37-8.27)

11.4

-

Gender

Female

1

0.00187

26.5

27.0

Male

1.38 (0.84-2.27)

16.6

8.6

Stage

St IA+IB

1

0.00000

38.1

54.2

St IIA+IIB

2.28 (1.18-4.34)^*

27.6

27.8

St IIIA+IIIB

12.67 (6.69-23.19)^*

11.9

5.8

St IV

22.56 (10.19-48.03)^*

7.8

3.9

pT

T₁

1

0.00000

33.6

40.2

T₂

1.85 (0.88-3.88)

27.2

25.0

T₃

5.43 (2.33-12.36)^*

11.7

15.2

T₄

19.68 (6.61-56.24)^*

9.6

1.1

pN

N₀

1

0.00000

34.3

46.6

N₁

6.73 (3.53-12.54)^*

17.8

9.6

N₂

19.49 (9.11-40.05)^*

11.5

6.1

N₃

5.41 (2.21-12.93)^*

5.7

5.3

pM

M₀

1

0.00000

23.2

26.0

M₁

7.45 (3.60-14.99)^*

7.8

1.4

Histological Types

ADC

1

0.00000

23.2

24.6

SCC

1.81 (1.10-2.95)^*

15.2

14.5

ADC + SCC

1.69 (0.33-8.46)

22.4

25.3

NEC (G1+G2)

0.08 (0.02-0.37)^*

48.9

80.0

NEC (G3)

2.69 (1.23-5.77)^*

11.1

8.3

Treatment

Radical

1

0.00000

37.0

45.1

Combined

3.65 (2.11-6.21)^*

26.2

24.3

Palliative

22.97 (10.92-46.31)^*

11.1

0.78

No treatment

43.05 (9.76-180.4)^*

2.9

-